FindTrial
Sign In

A pilot, open, monocenter, randomized two parallel groups, clinical efficacy trial: Comparison continuous versus on demand regimen of treatment with Levocetirizine 5 mg oral tablets, once a day, in adults suffering from PErsistent allergic Rhinitis (PER) over 6 months

A pilot, open, monocenter, randomized two parallel groups, clinical efficacy trial: Comparison continuous versus on demand regimen of treatment with Levocetirizine 5 mg oral tablets, once a day, in adults suffering from PErsistent allergic Rhinitis (PER) over 6 months

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-003858-26-IT
Enrollment
100
Registered
2005-08-01
Start date
2005-03-02
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Allergy

Interventions

Trade Name: XYZAL*5MG 20 CPR RIV Product Name: NA Product Code: NA Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Levocetirizine Concentration unit: mg milligram(s) Concentration type: e

Sponsors

UCB PHARMA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026